chemieunternehmen.com

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-endometriosis-programme-into-phase-i-clinical-development-and-extend-alliance-5478

Evotec AG announced today that the Company has been awarded a ‚Programm für Innovation‘ („PROFI“) grant for a period of two years from the  Hamburgische Investitions- und Förderbank Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-received-funding-from-ifb-hamburg-to-identify-antibody-mediated-t-cell-immunotherapies-5476

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. („Censo“) to source and provide patient-derived induced pluripotent stem cells („iPSC“) to support Evotec’s broad iPSC platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-drug-discovery-leadership-through-strategic-collaboration-with-censo-biotechnologies-5474

Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab282-accelerates-with-second-round-funding-5472

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies‘ („Facio“) 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy („FSHD“) community (Total volume: EUR 4.8 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-strategic-investment-in-facio-therapies-to-support-development-of-novel-fshd-therapy-5470

Evotec AG was awarded the European Mediscience Award for “Company of the Year”.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-european-mediscience-award-for-company-of-the-year-5467

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney diseasefocused drug discovery based on patient derived-data. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-joins-nurture-consortium-to-mine-unique-kidney-disease-patient-biobank-5464

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting, which took place today, with the required majority. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/resolutions-of-the-annual-general-meeting-2017-of-evotec-ag-5466

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017 Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/forge-therapeutics-and-evotec-present-first-efficacy-data-for-lpxc-inhibitor-in-uti-model-at–asm-microbe-2017-5461